MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 841-850

  Rocci, Alberto ^a   Gambella, Manuela ^a   Aschero, Simona ^a   Baldi, Ileana ^b   Trusolino, Livio ^c,d   Cavallo, Federica ^a   Gay, Francesca ^a   Larocca, Alessandra ^a   Magarotto, Valeria ^a   Omedè, Paola ^a   Isaia, Gianluca ^d   Bertotti, Andrea ^c,d   Liberati, Anna M ^e   Catalano, Lucio ^f   De Rosa, Luca ^g   Musto, Pellegrino ^h   Vallone, Roberto ⁱ   Falcone, Antonietta ^j   Drandi, Daniela ^a   Ladetto, Marco ^a   Comoglio, Paolo M ^c,d   Boccadoro, Mario ^a   Palumbo, Antonio ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁱ G RUMMO HOSPITAL   (Italy)

^j Divisione di Ematologia   (Italy)

more..

Author keywords

Biomarker; Hepatocyte growth factor; MET; Multiple myeloma; Prognostic factor

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; MESSENGER RNA; PREDNISONE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SYNDECAN 1; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT RESPONSE;

BIOMARKER; HEPATOCYTE GROWTH FACTOR; MET; MULTIPLE MYELOMA; PROGNOSTIC FACTOR;

AGED; AGED, 80 AND OVER; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84896701281     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12719     Document Type: Article

References (31)

1. Börset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A. & Waage, A. (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood, 88, 3998-4004.
2. Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., Del Grammastro, M., Sciarrotta, M.G., Buttitta, F., Incarbone, M., Toschi, L., Finocchiaro, G., Destro, A., Terracciano, L., Roncalli, M., Alloisio, M., Santoro, A. & Varella-Garcia, M. (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. Journal of Clinical Oncology, 27, 1667-1674.
3. Comoglio, P.M., Giordano, S. & Trusolino, L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Review. Drug Discovery, 7, 504-516.
4. Danilkovitch-Miagkova, A. & Zbar, B. (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. The Journal of Clinical Investigation, 109, 863-867.
5. Derksen, P.W., Keehnen, R.M., Evers, L.M., van Oers, M.H., Spaargaren, M. & Pals, S.T. (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood, 99, 1405-1410.
6. Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V.; International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
7. Galimi, F., Torti, D., Sassi, F., Isella, C., Corà, D., Gastaldi, S., Ribero, D., Muratore, A., Massucco, P., Siatis, D., Paraluppi, G., Gonella, F., Maione, F., Pisacane, A., David, E., Torchio, B., Risio, M., Salizzoni, M., Capussotti, L., Perera, T., Medico, E., Di Renzo, M.F., Comoglio, P.M., Trusolino, L. & Bertotti, A. (2011) Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clinical Cancer Research, 17, 3146-3156.
8. Graziano, F., Galluccio, N., Lorenzini, P., Ruzzo, A., Canestrari, E., D'Emidio, S., Catalano, V., Sisti, V., Ligorio, C., Andreoni, F., Rulli, E., Di Oto, E., Fiorentini, G., Zingaretti, C., De Nictolis, M., Cappuzzo, F. & Magnani, M. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. Journal of Clinical Oncology, 29, 4789-4795.
9. Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Hollmig, K., Zangarri, M., Pineda-Roman, M., van Rhee, F., Cavallo, F., Burington, B., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, J.D. Jr (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 108, 1724-1732.
10. Hastie, T. & Tibshirani, R. (1990) Generalized Additive Models. Chapman & Hall, London, UK.
11. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G. & Anderson, K.C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Review Cancer, 7, 585-598.
12. Holt, R.U., Fagerli, U.M., Baykov, V., Rø, T.B., Hov, H., Waage, A., Sundan, A. & Børset, M. (2008) Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica, 93, 619-622.
13. Ke, A.W., Shi, G.M., Zhou, J., Wu, F.Z., Ding, Z.B., Hu, M.Y., Xu, Y., Song, Z.J., Wang, Z.J., Wu, J.C., Bai, D.S., Li, J.C., Liu, K.D. & Fan, J. (2007) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology, 49, 491-503.
14. Kristensen, I.B., Christensen, J.H., Lyng, M.B., Møller, M.B., Pedersen, L., Rasmussen, L.M., Ditzel, H.J. & Abildgaard, N. (2013) Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. British Journal of Haematology, 161, 373-382.
15. Lennerz, J.K., Kwak, E.L., Ackerman, A., Michael, M., Fox, S.B., Bergethon, K., Lauwers, G.Y., Christensen, J.G., Wilner, K.D., Haber, D.A., Salgia, R., Bang, Y.J., Clark, J.W., Solomon, B.J. & Iafrate, A.J. (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology, 29, 4803-4810.
16. Mahtouk, K., Tjin, E.P., Spaargaren, M. & Pals, S.T. (2010) The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochimica et Biophysica Acta, 1806, 208-219.
17. Munshi, N.C., Anderson, K.C., Bergsagel, P.L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, R., Stewart, A.K., Harousseau, J.L., Dimopoulos, M., Jagannath, S., Hajek, R., Sezer, O., Kyle, R., Sonneveld, P., Cavo, M., Rajkumar, S.V., San Miguel, J., Crowley, J. & Avet-Loiseau, H.; International Myeloma Workshop Consensus Panel 2. (2011) Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 117, 4696-4700.
18. Palumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., Guglielmelli, T., Bringhen, S., Offidani, M., Giuliani, N., Petrucci, M.T., Musto, P., Liberati, A.M., Rossi, G., Corradini, P. & Boccadoro, M. (2010a) Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Journal of Clinical Oncology, 28, 800-807.
19. Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. (2010b) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101-5109.
20. Podar, K., Tai, Y.T., Lin, B.K., Narsimhan, R.P., Sattler, M., Kijima, T., Salgia, R., Gupta, D., Chauhan, D. & Anderson, K.C. (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. The Journal of Biological Chemistry, 277, 7875-7881.
21. Que, W., Chen, J., Chuang, M. & Jiang, D. (2012) Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS, 120, 195-203.
22. Ross, F.M., Avet-Loiseau, H., Ameye, G., Gutiérrez, N.C., Liebisch, P., O'Connor, S., Dalva, K., Fabris, S., Testi, A.M., Jarosova, M., Hodkinson, C., Collin, A., Kerndrup, G., Kuglik, P., Ladon, D., Bernasconi, P., Maes, B., Zemanova, Z., Michalova, K., Michau, L., Neben, K., Hermansen, N.E., Rack, K., Rocci, A., Protheroe, R., Chiecchio, L., Poirel, H.A., Sonneveld, P., Nyegaard, M., Johnsen, H.E.; European Myeloma Network. (2012) Report from the european myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica, 97, 1272-1277.
23. Sawada, K., Radjabi, A.R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A.R., Turkyilmaz, M.A., Salgia, R., Yamada, S.D., Vande Woude, G.F., Tretiakova, M.S. & Lengyel, E. (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research, 67, 1670-1679.
24. Spigel, D.R., Ervin, T.J., Ramlau, R., Daniel, D.B., Goldschmidt, J.H., Blumenschein, G.R., Krzakowski, M.J., Robinet, G., Clement-Duchene, C., Barlesi, F., Govindan, R., Patel, T., Orlov, S.V., Wertheim, M.S., Zha, J., Pandita, A., Yu, W., Yauch, R.L., Patel, P.H. & Peterson, A.C. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology, 29, (abstract 7505).
25. Standal, T., Abildgaard, N., Fagerli, U.M., Stordal, B., Hjertner, O., Borset, M. & Sundan, A. (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood, 109, 3024-3030.
26. Stein, U., Walther, W., Arlt, F., Schwabe, H., Smith, J., Fichtner, I., Birchmeier, W. & Schlag, P.M. (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature Medicine, 15, 59-67.
27. Teofili, L., Di Febo, A.L., Pierconti, F., Maggiano, N., Bendandi, M., Rutella, S., Cingolani, A., Di Renzo, N., Musto, P., Pileri, S., Leone, G. & Larocca, L.M. (2001) Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood, 97, 1063-1069.
28. Tjin, E.P., Groen, R.W., Vogelzang, I., Derksen, P.W., Klok, M.D., Meijer, H.P., van Eeden, S., Pals, S.T. & Spaargaren, M. (2006) Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood, 107, 760-768.
29. Trusolino, L., Bertotti, A. & Comoglio, P.M. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nature Review. Molecular Cell Biology, 11, 834-848.
30. Wader, K.F., Fagerli, U.M., Børset, M., Lydersen, S., Hov, H., Sundan, A., Bofin, A. & Waage, A. (2012) Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology, 60, 443-451.
31. Yap, T.A., Olmos, D., Brunetto, A.T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., Collins, D., deSouza, N.M., Leach, M.O., Savage, R.E., Waghorne, C., Chai, F., Garmey, E., Schwartz, B., Kaye, S.B. & de Bono, J.S. (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. Journal of Clinical Oncology, 29, 1271-1279.